<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876433</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004805-29</org_study_id>
    <nct_id>NCT01876433</nct_id>
  </id_info>
  <brief_title>Beta 3 Agonist Treatment in Heart Failure</brief_title>
  <acronym>Beat-HF</acronym>
  <official_title>Beta 3 Agonist Treatment in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bundgaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study is to assess the structural and functional cardiac&#xD;
      effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart&#xD;
      failure.&#xD;
&#xD;
      Design: The investigators are planning a study aiming at establishing proof of concept that&#xD;
      treatment of patients with HF with Mirabegron has significant positive effects, as assessed&#xD;
      by clinical and biochemistry measurements, but not by hard endpoints. The investigators are&#xD;
      performing a combined dose-finding - chronic efficacy study.&#xD;
&#xD;
      The study is a randomized, placebo-controlled, double-blinded trial. The follow-up period is&#xD;
      6 months. 70 patients with chronic heart failure will be included.&#xD;
&#xD;
      Specific aims&#xD;
&#xD;
        1. Determine safety of administration of Mirabegron to patients with heart failure.&#xD;
&#xD;
        2. Determine if treatment with Mirabegron for 6 months induces beneficial cardiac&#xD;
           structural remodelling in patients with heart failure.&#xD;
&#xD;
        3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by&#xD;
           questionnaires and 6 min walk test in patients with heart failure.&#xD;
&#xD;
        4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and&#xD;
           arrhythmias in patients with heart failure.&#xD;
&#xD;
        5. Determine effects of Mirabegron on circulating biomarkers in patients with heart&#xD;
           failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2013</start_date>
  <completion_date type="Actual">September 30, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in LVEF (measured by MRI or CT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A reduction in NT proBNP</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An increase in 6 min walking distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An increase in CO/SV</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LVIDd</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An improvement in diastolic function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LA volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LV diameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A shortening of the QT interval</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>6 monhs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in functional class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)</condition>
  <arm_group>
    <arm_group_label>Beta-3-agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <arm_group_label>Beta-3-agonist</arm_group_label>
    <other_name>Beta 3 agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stable heart failure NYHA class II-III on ischemic or non-ischemic basis&#xD;
&#xD;
          2. Left ventricular ejection fraction (LVEF) &lt; 40%&#xD;
&#xD;
          3. Stable sinus rhythm (SR)&#xD;
&#xD;
          4. On optimised evidence-based pharmacological HF treatment stable &gt; 4 weeks with no&#xD;
             current plan for changing HF therapy. The therapy must include a beta-blocker.&#xD;
&#xD;
          5. No change in diuretics &lt; 4 weeks&#xD;
&#xD;
          6. &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable cardiac condition&#xD;
&#xD;
          2. Acute myocardial infarction (AMI) or revascularisation &lt; 3 month ago&#xD;
&#xD;
          3. Atrial fibrillation (for technical reasons in relation to imaging and HR reporting)&#xD;
&#xD;
          4. Uncorrected significant primary obstructive valve disease&#xD;
&#xD;
          5. Planned major surgery including cardiac revascularisation&#xD;
&#xD;
          6. Hemodynamically significant obstructive cardiomyopathy&#xD;
&#xD;
          7. Stroke with significant neurological deficit&#xD;
&#xD;
          8. Acute myocarditis or constrictive pericarditis&#xD;
&#xD;
          9. Symptomatic bradycardia or &gt; 1. degree AV-block unless the patient has a pacemaker&#xD;
&#xD;
         10. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference&#xD;
             level) or renal (GFR&lt; 50 ml/min/1,73 m2) diseases&#xD;
&#xD;
         11. Heart failure due to uncorrected thyroid disease&#xD;
&#xD;
         12. Cardiac mechanical support&#xD;
&#xD;
         13. &lt; 6 months after CRT&#xD;
&#xD;
         14. Uncontrolled hypotension (defined as symptomatic systolic blood pressure &lt; 90 mmHg) -&#xD;
             or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood&#xD;
             pressure at 110 mmHg or below)&#xD;
&#xD;
         15. Body mass index (BMI) &gt; 35&#xD;
&#xD;
         16. Unable to give informed consent&#xD;
&#xD;
         17. Reduced compliance&#xD;
&#xD;
         18. All women of child bearing potential will be required to use adequate contraception&#xD;
&#xD;
         19. Pregnant or lactating women&#xD;
&#xD;
         20. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than&#xD;
             beta-blockers or treatment with digoxin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bundgaard, MD, PhD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet Copenhagen University Hospital, Department of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monash Center of Cardiovascular Research.</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Royal North Shore Hospital.</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital.</name>
      <address>
        <city>Copenhagen Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henning Bundgaard</investigator_full_name>
    <investigator_title>Consultant, dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

